AU2014292377B2 - Targeted modified IL-1 family members - Google Patents

Targeted modified IL-1 family members Download PDF

Info

Publication number
AU2014292377B2
AU2014292377B2 AU2014292377A AU2014292377A AU2014292377B2 AU 2014292377 B2 AU2014292377 B2 AU 2014292377B2 AU 2014292377 A AU2014292377 A AU 2014292377A AU 2014292377 A AU2014292377 A AU 2014292377A AU 2014292377 B2 AU2014292377 B2 AU 2014292377B2
Authority
AU
Australia
Prior art keywords
targeting
cells
targeting construct
construct according
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014292377A
Other languages
English (en)
Other versions
AU2014292377A1 (en
Inventor
Sarah Gerlo
Frank Peelman
Jan Tavernier
Gilles Uze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier filed Critical Universiteit Gent
Publication of AU2014292377A1 publication Critical patent/AU2014292377A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITEIT GENT, VIB VZW, UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Amend patent request/document other than specification (104) Assignors: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2, UNIVERSITEIT GENT, VIB VZW
Application granted granted Critical
Publication of AU2014292377B2 publication Critical patent/AU2014292377B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2014292377A 2013-07-19 2014-07-04 Targeted modified IL-1 family members Active AU2014292377B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306047.5 2013-07-19
EP13306047 2013-07-19
PCT/EP2014/064283 WO2015007542A1 (en) 2013-07-19 2014-07-04 Targeted modified il-1 family members

Publications (2)

Publication Number Publication Date
AU2014292377A1 AU2014292377A1 (en) 2016-02-04
AU2014292377B2 true AU2014292377B2 (en) 2019-08-01

Family

ID=48874235

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014292377A Active AU2014292377B2 (en) 2013-07-19 2014-07-04 Targeted modified IL-1 family members

Country Status (14)

Country Link
US (5) US9932409B2 (cg-RX-API-DMAC7.html)
EP (1) EP3022226B1 (cg-RX-API-DMAC7.html)
JP (1) JP6475713B2 (cg-RX-API-DMAC7.html)
KR (1) KR102275090B1 (cg-RX-API-DMAC7.html)
CN (1) CN105612180B (cg-RX-API-DMAC7.html)
AU (1) AU2014292377B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016001128A2 (cg-RX-API-DMAC7.html)
CA (1) CA2918518C (cg-RX-API-DMAC7.html)
DK (1) DK3022226T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714504T3 (cg-RX-API-DMAC7.html)
IL (1) IL243466B (cg-RX-API-DMAC7.html)
MX (1) MX370348B (cg-RX-API-DMAC7.html)
SG (1) SG11201600167SA (cg-RX-API-DMAC7.html)
WO (1) WO2015007542A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018008390A2 (pt) 2015-10-30 2018-11-27 Aleta Biotherapeutics Inc composições e métodos para transdução tumoral
MA43135A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
WO2017134301A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents
CN109069573B (zh) 2016-03-07 2022-04-05 弗拉芒区生物技术研究所 结合cd20的单结构域抗体
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN109689087B (zh) 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
JP7586579B2 (ja) 2017-02-06 2024-11-19 オリオンズ バイオサイエンス インコーポレイテッド 標的化改変型インターフェロン及びその使用
CN110546160A (zh) 2017-02-06 2019-12-06 奥里尼斯生物科学公司 靶向嵌合蛋白及其用途
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
AU2018226857B2 (en) * 2017-03-03 2025-01-02 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
CN111511764B (zh) 2017-08-09 2024-02-06 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
CA3069994A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Pd-1 and pd-l1 binding agents
US11970537B2 (en) * 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
AU2019215440B2 (en) 2018-02-05 2025-12-04 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
WO2020097350A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
CN113767115B (zh) 2019-03-28 2025-05-02 奥里尼斯生物科学股份有限公司 治疗性干扰素α1蛋白
KR20220012227A (ko) 2019-03-28 2022-02-03 오리오니스 바이오사이언시즈 인코포레이티드 Clec9a-기반 키메라 단백질 복합체
CA3185087A1 (en) * 2020-07-07 2022-01-13 Nikolai Kley Immunostimulatory adjuvants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2011020783A2 (en) * 2009-08-17 2011-02-24 Roche Glycart Ag Targeted immunoconjugates
WO2011029870A1 (en) * 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489116B1 (en) 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
WO2001029870A1 (en) * 1999-10-21 2001-04-26 Sarnoff Corporation Bi-potential electrode space-saving cathode ray tube
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
EP2052081A1 (en) 2006-08-02 2009-04-29 McGill University Fusion proteins and methods for modulation of immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
WO2010036918A2 (en) * 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
AU2009326075B2 (en) 2008-12-08 2014-06-05 Complix Nv Single-chain antiparallel coiled coil proteins
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
US9492562B2 (en) 2012-01-20 2016-11-15 Vib Vzw Targeted human-interferon fusion proteins
HRP20200918T1 (hr) 2012-03-03 2020-11-27 Immungene, Inc. Modificirane mutirane fuzijske molekule interferonskog antitijela

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2011020783A2 (en) * 2009-08-17 2011-02-24 Roche Glycart Ag Targeted immunoconjugates
WO2011029870A1 (en) * 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes

Also Published As

Publication number Publication date
US20230235086A1 (en) 2023-07-27
US20160152730A1 (en) 2016-06-02
ES2714504T3 (es) 2019-05-28
CA2918518A1 (en) 2015-01-22
US20180186894A1 (en) 2018-07-05
IL243466A0 (en) 2016-03-31
EP3022226A1 (en) 2016-05-25
JP6475713B2 (ja) 2019-02-27
MX370348B (es) 2019-12-10
US20200255545A1 (en) 2020-08-13
CA2918518C (en) 2022-08-16
BR112016001128A2 (pt) 2018-01-23
CN105612180B (zh) 2019-11-12
CN105612180A (zh) 2016-05-25
US20190202934A1 (en) 2019-07-04
JP2016527221A (ja) 2016-09-08
WO2015007542A1 (en) 2015-01-22
SG11201600167SA (en) 2016-02-26
AU2014292377A1 (en) 2016-02-04
EP3022226B1 (en) 2018-12-05
MX2016000723A (es) 2016-12-20
KR20160108293A (ko) 2016-09-19
KR102275090B1 (ko) 2021-07-09
DK3022226T3 (en) 2019-03-25
US9932409B2 (en) 2018-04-03
IL243466B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US20230235086A1 (en) Targeted modified il-1 family members
JP7714710B2 (ja) アルブミン結合ドメイン融合タンパク質
CN106659757A (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
TW200539891A (en) Methods of modulating cytokine activity; related reagents
JP2021527047A (ja) 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
US20240376172A1 (en) Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
US20240156980A1 (en) Protease cleavable prodrugs
JP2025000998A (ja) ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
HK1225048B (en) Targeted modified il-1 family members
HK1225048A1 (en) Targeted modified il-1 family members
JPWO2005023853A1 (ja) プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
CN117242094A (zh) 蛋白酶可切割的前药

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: UNIVERSITE DE MONTPELLIER

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: VIB VZW

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTP

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

Owner name: UNIVERSITEIT GENT

Free format text: FORMER NAME(S): CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER; VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE MONTPELLIER 2

FGA Letters patent sealed or granted (standard patent)